VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ETON
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ETONEton Pharmaceuticals, Inc.
$63.88$1.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ETON
  4. Financial Ratios

Eton Pharmaceuticals, Inc. (ETON) Financial Ratios

Latest Ratios: P/E Ratio 42.6x · EV/EBITDA 38.4x · ROE -18.2%. (2017–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ETON Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$1.7B$455M$345M$112M$71M$108M$171M$128M$39M—
Enterprise Value$1.8B$460M$360M$96M$61M$100M$157M$120M$13M—
P/E Ratio →42.62—————————
P/S Ratio12.405.698.843.553.344.954379.78133.35——
P/B Ratio65.7217.4014.127.265.426.1310.9112.121.49—
P/FCF45.7944.65365.7718.6034.88—————
P/OCF166.2743.24355.9616.4814.71—————

P/E links to full P/E history page with 30-year chart

ETON EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue—5.759.233.042.884.604016.88125.52——
EV / EBITDA38.43111.78————————
EV / EBIT9999.002063.19————————
EV / FCF—45.15381.7415.9530.07—————

ETON Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin53.5%53.5%60.0%66.6%67.4%88.0%-633.3%52.8%——
Operating Margin0.1%0.1%-6.7%-3.8%-38.9%-6.8%-69515.4%-1939.6%——
Net Profit Margin-5.8%-5.8%-9.8%-3.0%-42.4%-9.0%-71717.9%-1910.3%——

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE-18.2%-18.2%-19.2%-6.6%-58.8%-11.7%-213.4%-99.4%-66.3%-59.0%
ROA-5.5%-5.5%-7.1%-3.3%-34.4%-7.3%-128.9%-80.7%-61.0%-53.2%
ROIC0.2%0.2%-10.0%-64.1%-93.8%-19.6%-893.2%-1068.6%——
ROCE0.1%0.1%-7.2%-7.0%-39.8%-6.6%-144.1%-89.8%-53.0%-56.5%

ETON Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity1.191.191.230.350.500.380.460.43——
Debt / EBITDA7.547.54————————
Net Debt / Equity—0.190.62-1.03-0.75-0.44-0.90-0.71-1.02-1.08
Net Debt / EBITDA1.231.23————————
Debt / FCF—0.5015.97-2.65-4.81—————
Interest Coverage0.050.05-0.90-0.65-9.45-1.88-30.50———

ETON Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio1.571.572.061.653.105.186.517.6513.5916.76
Quick Ratio1.171.171.291.603.015.066.187.4513.5916.76
Cash Ratio0.670.670.751.322.523.165.616.1513.2116.59
Asset Turnover—0.870.511.000.850.790.000.06——
Inventory Turnover2.412.411.0211.6112.454.770.231.19——
Days Sales Outstanding—53.6750.1639.3531.8191.47449.23180.03——

ETON Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield————————2.7%—
Payout Ratio——————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield2.3%—————————
FCF Yield2.2%2.2%0.3%5.4%2.9%—————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%—
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%2.7%—
Shares Outstanding—$27M$26M$26M$25M$25M$21M$18M$6M$17M

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Thin margins and leverage

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Price in Sustained Growth

Based on reported figures, ETON trades at 37.67x trailing earnings, 33.98x EV/EBITDA, and 10.96x sales, multiples that imply investors are pricing in a durable scale-up of the orphan portfolio rather than current earnings power. These levels sit well above what a near-breakeven specialty pharma would normally command.

The forward P/E of 51.95 exceeds the trailing multiple, which suggests the market expects earnings to lag near-term revenue growth or that forward estimates are being revised downward, a pattern that warrants monitoring. A price-to-book of 58.09 reflects an equity base that is small relative to market value and is largely built from recent earnings rather than tangible capital. Investors should treat these multiples as contingent on margin conversion, since the trailing net margin of -5.8% offers little support for a multiple of this magnitude.

Margin Rebuild Outpaces Earnings Conversion

As reported in financial statements, ETON's gross margin rose from 35.0% in 2025Q3 to 76.5% in 2026Q3, yet trailing net margin remains -5.8%, showing that top-line gains have not yet translated into sustained bottom-line profitability.

The gross margin rebuild suggests a meaningful shift toward higher-value products and better unit economics, but operating margin of 39.7% in the latest quarter compares with a near-zero trailing operating margin of 0.1%, indicating the recent quarterly improvement is concentrated and not yet proven recurring. The gap between gross and net margin implies that operating expenses and below-the-line items continue to absorb most of the gross profit. Earnings quality should be judged on whether the latest quarter's margin level holds over several subsequent periods.

Returns Turn Positive But Remain Unproven

Based on ETON's reported figures, ROE moved from -10.7% in 2025Q2 to 52.8% in 2026Q3, while trailing ROE stands at -18.2%, so the recent swing reflects a few strong quarters against a longer negative base.

The jump in quarterly ROE to 52.8% is substantially inflated by a small equity base and a single strong earnings period, which limits its usefulness as a measure of durable capital efficiency. ROIC of 33.2% in the latest quarter compares with negative returns in 2025, suggesting the company may be moving from value destruction toward value creation, though this conclusion requires several more quarters to confirm. Investors should compare these figures against a sustained run of positive ROIC before treating the inflection as structural.

Debt Service Comfort Improves With Earnings

According to recent reported filings, ETON's debt-to-equity fell to 0.28 in 2026Q3 from 0.62 a quarter earlier, while interest coverage rose to 24.31x, indicating debt service has become considerably more comfortable as earnings recovered.

Total debt of $24.1M against a rebuilt equity base of $86.9M reduces the risk that interest obligations crowd out operations, and the coverage ratio suggests current earnings can absorb debt costs many times over. However, coverage was negative in several earlier quarters, so the improvement is recent and depends on operating income holding. Refinancing exposure and covenant terms are not detailed in the supplied data, so this assessment is limited to the reported ratios.

Cash Buffer Rebuilt Through Recent Inflows

As reported in financial statements, ETON's current ratio of 1.79 and quick ratio of 1.58 in 2026Q3 reflect a cash position of $55.6M, up from $19.7M in 2026Q1, indicating a liquidity buffer that has strengthened meaningfully within two quarters.

The quick ratio sitting close to the current ratio suggests inventory is a modest share of current assets, which lowers dependence on inventory conversion under stress. The rapid cash rebuild appears driven by operating inflows and working capital timing rather than external financing, though the reported data does not fully isolate these sources. Under a severe demand shock, the current cash balance would cover several quarters of the recent operating burn levels, but sustained profitability would still be needed for the buffer to grow.

Working Capital Cycle Compresses Sharply

Based on EDBL's reported figures, ETON's cash conversion cycle narrowed from 207 days in 2025Q2 to 8 days in 2026Q3, driven by falling inventory days from 243 to 72 and receivable days from 74 to 41.

The compression in inventory days suggests tighter production planning or faster wholesaler sell-through, which reduces the cash tied up in working capital. Payable days of 104 are high relative to receivable days, indicating the company is leaning on supplier credit to fund operations, a dependence that could reverse if vendors tighten terms. Investors should monitor whether the short cycle persists as revenue scales, since a return to earlier inventory levels would reintroduce meaningful cash drag.

Misapplied Gross Margin Obscures Net Economics

The most commonly misapplied ratio for this business is the quarterly gross margin of 76.5%, which appears to overstate earning power because gross-to-net adjustments, royalties, and launch timing are not reflected in the headline figure.

For a specialty pharma company operating under a 505(b)(2) model with orphan indications, gross margin can be inflated by revenue recognized before rebates, chargebacks, and co-pay programs are fully netted, and by milestone or licensing receipts that do not recur. A more reliable measure is net income adjusted for non-recurring items, or cash-based earnings power such as free cash flow margin across multiple quarters. The trailing net margin of -5.8% and ROE of -18.2% suggest that gross margin alone should not anchor a valuation view.

Download Financial Ratios Data

Includes 30+ ratios · 9 years · Updated daily

Consensus & Technical Research Suite
Open ETON Terminal

ETON Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ETON — Frequently Asked Questions

Quick answers to the most common questions about buying ETON stock.

What is Eton Pharmaceuticals, Inc.'s P/E ratio?

Eton Pharmaceuticals, Inc.'s current P/E ratio is 42.6x. This places it at the 50th percentile of its historical range.

What is Eton Pharmaceuticals, Inc.'s EV/EBITDA?

Eton Pharmaceuticals, Inc.'s current EV/EBITDA is 38.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.

What is Eton Pharmaceuticals, Inc.'s ROE?

Eton Pharmaceuticals, Inc.'s return on equity (ROE) is -18.2%. The historical average is -61.4%.

Is ETON stock overvalued?

Based on historical data, Eton Pharmaceuticals, Inc. is trading at a P/E of 42.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Eton Pharmaceuticals, Inc.'s profit margins?

Eton Pharmaceuticals, Inc. has 53.5% gross margin and 0.1% operating margin.

How much debt does Eton Pharmaceuticals, Inc. have?

Eton Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 7.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.